{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-076214","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.772722+00:00","generated_at":"2026-05-17T15:34:11.036070+00:00","sec_items":["7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioXcel Therapeutics raises $30.4M net, satisfies Oaktree financing covenant","bullets":["Raised $30.4M net from Nov 2024 ($6.2M), Mar 2025 ($13.0M), and ATM ($11.2M) financings, satisfying the Oaktree Financing Covenant.","Covenant required $29M net by Aug 15, 2025 or 30 days after SERENITY Phase 3 final readout; now satisfied.","As of Aug 8, 2025, BioXcel had 13,709,124 shares outstanding post-exercise of all pre-funded warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-076214","json":"https://secwatch.observer/filing/0001104659-25-076214.json","markdown":"https://secwatch.observer/filing/0001104659-25-076214.md","text":"https://secwatch.observer/filing/0001104659-25-076214.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925076214/0001104659-25-076214-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925076214/tm2523144d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:34:11.036070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}